Macimorelin (INN) – or Macrilen (trade name) – is a drug that was developed by Aeterna Zentaris for use in the diagnosis of adult growth hormone deficiency.

[3] Macimorelin acetate, the salt formulation, is a synthetic growth hormone secretagogue receptor agonist.

Macimorelin (Macrilen) was invented and first synthesized at University of Montpellier, Centre National de la Recherche Scientitifique (CNRS), France.

[11] The phase III trial for growth hormone deficiency is expected to be complete in December 2016.

These two means are done parenterally, whereas Macrilen boasts an oral formulation for ease of administration for patients and providers.